Gosselies, Belgium, 10 March 2017, 9am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it will participate in the following upcoming key investor conferences:
BioCapital Europe
Date: 15 March
Venue: Amsterdam, The Netherlands
Portzamparc Mid & Small Cap Conference
Date: 21-22 March
Venue: Paris, France
KBC Securities Healthcare Conference
Date: 29 March
Venue: Brussels, Belgium
European SmallCap Event
Date: 18-19 April
Venue: Paris, France
ARM Cell & Gene Therapy Investor Day
Date: 27 April
Venue: Boston, USA
Bone Therapeutics will also be present at the following partnering conference and retail event:
VFB Happening
Date: 25 March
Venue: Antwerp, Belgium
Knowledge for Growth
Date: 18 May
Venue: Ghent, Belgium
About Bone Therapeutics
Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for orthopaedics and bone diseases. The current standard of care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs for the development of novel product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at: www.bonetherapeutics.com.
